New treatment options for infections caused by increasingly antimicrobial-resistant Neisseria gonorrhoeae.
The emergence of high-level resistance to ceftriaxone is giving rise to serious concern about absence of effective treatment options to cure gonococcal infections. Increasing the dosage regimen can be applied to ceftriaxone and azithromycin, but the emergence of high-level resistance has already been reported. Spectinomycin is another active drug but has low efficacy in the treatment of pharyngeal gonorrhoea. Conventional antibiotics could be introduced for gonococcal treatment, but they have some limitations, such as the absence of clinical trials and breakpoint. Combining antibiotics is another promising method to cure patients and to prevent the emergence of resistance. The most important strategy to maintain the efficacy of antibiotics is rapid detection and dissemination control of novel resistant isolate.
['Lee|Hyukmin|H|', 'Lee|Kyungwon|K|', 'Chong|Yunsop|Y|']
D000900:Anti-Bacterial Agents D017963:Azithromycin D001463:Barbiturates D002443:Ceftriaxone D024881:Drug Resistance, Bacterial D004359:Drug Therapy, Combination D006069:Gonorrhea D006801:Humans D007555:Isoxazoles D018942:Macrolides D009025:Morpholines D009344:Neisseria gonorrhoeae D016870:Neisseriaceae Infections D023303:Oxazolidinones D010612:Pharyngitis D000198:Spectinomycin D013141:Spiro Compounds D014230:Triazoles
New treatment options Neisseria gonorrhoeae Ceftriaxone Azithromycin Spectinomycin Combination therapy Dual therapy ETX0914 Solithromycin